Chemical structure of phenothiazines and their biological activity

Pharmacological Reports

Volumn 64, Issue 1, 2012, Pages 16-23

  Jaszczyszyn, Agata ^a   Ga̧siorowski, Kazimierz ^a   Świa̧tek, Piotr ^a   Malinka, Wiesław ^a   Cieślik Boczula, Katarzyna ^b   Petrus, Joanna ^b   Czarnik Matusewicz, Bogusława ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF WROC AW   (Poland)

Author keywords

Antipsychotics; Calmodulin; Multidrug resistance; P glycoprotein; Phenothiazine derivatives; Protein kinase C

Indexed keywords

CALMODULIN; GLYCOPROTEIN P; PHENOTHIAZINE DERIVATIVE; PROTEIN KINASE;

ANTIMULTIDRUG RESISTANCE ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIPSYHOTIC ACTIVITY; CHEMICAL MODIFICATION; CHEMOPROPHYLAXIS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; HYDROGEN BOND; HYDROPHILICITY; HYDROPHOBICITY; LIPOPHILICITY; PROTEIN EXPRESSION; REVIEW; STRUCTURE ANALYSIS; SUBSTITUTION REACTION;

EID: 84862187466     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70726-0     Document Type: Review

References (53)

1. Aftab DT, Ballas LM, Loomis CR, Hait WN: Structure-activity relationships of phenothiazines and related drugs for inhibition of protein kinase C. Mol Pharmacol, 1991, 40, 798-805.
2. Ahmad S, Safa AR, Glazar RI:Modulation of P-glycoprotein by protein kinase Ca in a baculovirus expression system. Biochemistry, 1994, 33, 10313-10318. (Pubitemid 24281796)
3. Chambers TC, McAvoy EM, Jacobs JW, Eilon G: Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem, 1990, 265, 7679-7686.
4. Chambers TC, Pohl J, Raynor RL, Kuo JF: Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J Biol Chem, 1993, 268, 4592-4595. (Pubitemid 23081564)
5. Chen JY, Brunauer LS, Chu FC, Helsel CM, Gedde MM, Huestis WH: Selective amphipatic nature of chlorpromazine binding to plasma membrane bilayers. Biochim Biophys Acta, 2003, 1616, 95-105. (Pubitemid 37272117)
6. Chen KH, Lin CE, Liao WS, Lin WY, Hsiao YY: Separation and migration behavior of structurally related phenothiazines in cyclodextrin-modified capillary zone electrophoresis. J Chromatogr A, 2002, 979, 399-408.
7. Cheung RK, Grinstein S, Gelfand EW: Permissive role of calcium in the inhibition of T cell mitogenesis by calmodulin antagonists. J Immunol, 1983, 131, 5, 2291-2295. (Pubitemid 14227425)
8. Cheung WY: Calmodulin plays a pivotal role in cellular regulation. Science, 1980, 207, 19-27.
9. 31P NMR studies. J Phys Chem B, 2009, 113, 47, 15495-15502.
10. De Ruiter J: Dopamine antagonists: phenothiazine/thioxanthene sar. In: Principles of Drug Action: The Basis of Pharmacology. Ed. Pratt WB and Taylor P, Churchill Livingstone, New York, 1990, 1-14.
11. Ecker G, Huber M, Schmid D, Chiba P: The importance of a nitrogen atom in modulators of multidrug resistance. Mol Pharmacol, 1999, 56, 791-796. (Pubitemid 29491182)
12. Ermak G, Davies KJA: Calcium and oxidative stress: from cell signaling to cell death. Mol Immunol, 2001, 38, 713-721.
13. Ford JM: Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer, 1996, 32A, 991-1001.
14. Ford JM, Prozialeck WC, Hait WN: Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol, 1988, 35, 105-115. (Pubitemid 19048639)
15. Ganapathi R, Kuo T, Teeter L, Grabowski D, Ford J: Relationship between of P glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells. Mol Pharmacol, 1991, 39, 1-8.
16. Hait WN, Aftab DT: Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance. Biochem Pharmacol, 1992, 43, 103-107.
17. Hait WN, Grais L, Benz C, Cadman EC: Inhibition growth of leukemic cells by inhibitors of calmodulin: phenothiazines and melittin. Cancer Chemother Pharmacol, 1985, 14, 202-205. (Pubitemid 15118638)
18. Hait WN, Lee GL: Characteristics of the cytotoxic effects of the phenothiazine class of calmodulin antagonists. Biochem Pharmacol, 1985, 34, 3973-3978. (Pubitemid 16193505)
19. Hendrich AB, Michalak K: Lipids as a target for drugs modulating multidrug resistance of cancer cells. Curr Drug Targets, 2003, 4, 23-30. (Pubitemid 36131638)
20. Hendrich AB, Wesołowska O, Motohashi N, Molnar J, Michalak K: New phenothiazine-type multidrug resistance modifiers: anti-MDR activity versus membrane perturbing potency. Biochem Biophys Res Commun, 2003, 304, 260-265. (Pubitemid 36444564)
21. Hendrich AB, Wesołowska O, Poła A, Motohashi N, Molnar J, Michalak K: Neither lipophilicity nor membrane-perturbing potency of phenothiazine maleates correlate with the ability to inhibit P-glycoprotein transport activity. Mol Membr Biol, 2003, 20, 53-60. (Pubitemid 36460646)
22. Jaszczyszyn A, Ga̧siorowski K: Mechanisms of chemopreventive activity of newly synthesized fluphenazine analogues (Polish). Borgis® Wydawnictwo Medyczne, Warszawa, 2006.
23. Liu R, Sharom FJ: Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains. Biochemistry, 1996, 35, 11865-11873. (Pubitemid 26303706)
24. Liu R, Siemiarczuk A, Sharom FJ: Intrinsic fluorescence of the P-glycoprotein multidrug transporter sensitivity of tryptophan residues to binding of drugs and nucleotides. Biochemistry, 2000, 39, 14927-14938.
25. Michalak K, Hendrich AB, Wesołowska O, Poła A: Compounds that modulate multidrug resistance in cancer cells. Cell Biol Mol Lett, 2001, 6, 362-368.
26. Michalak K, Hendrich AB, Wesołowska O, Pola A, Łania-Pietrzak B, Motohashi N, Shirataki Y, Molnar J: Lipid membrane perturbation caused by some isoflavones and phenothiazines, and the activity of these compounds as inhibitors of multidrug resistance. Cell Mol Biol Lett, 2002, 7, 2, 293.
27. Morak-Młodawska B, Jeleń M, Pluta K: New derivatives of phenothiazines with anticancer activities (Polish). Pol Merk Lek, 2009, 159, 671-675.
28. Motohashi N, Kawase M, Satoh K, Sakagami H: Cytotoxic potential of phenothiazine. Curr Drug Targets, 2006, 7, 1055-1066.
29. Mozrzymas JW, Barberis A, Michalak K, Cherubini E: Chlorpromazine inhibits miniature GABAergic currents by reducing the binding and by increasing the unbinding rate of GABAA receptors. J Neurosci, 1999, 19, 2474-2488. (Pubitemid 29162397)
30. Pajeva IK, Wiese M: QSAR and molecular modeling of catamphilic drugs able to modulate multidrug resistance in tumors. Quant Struct-Act Relat, 1997, 16, 1-10. (Pubitemid 27136067)
31. Pajeva IK, Wiese M, Cordes HP, Seydel JK: Membrane interactions of some catamphilic drugs and relation to their multidrug-resistance-reversing ability. J Cancer Res Clin Oncol, 1996, 122, 27-40.
32. Peroutka SJ, Snyder SH: Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic and histamine receptors to clinical potency. Am J Psychiatry, 1980, 137, 1518-1522. (Pubitemid 11196805)
33. Pluta K, Jeleń M, Morak-Młodawska B, Zimecki M, Artym J, Kociȩba M: Anticancer activity of newly synthesized azaphenothiazines from NCI's anticancer screening bank. Pharmacol Rep, 2010, 62, 319-332.
34. Ramu A, Ramu N: Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol, 1992, 30, 165-173.
35. Sakai TT, Krishna NR: Synthesis and properties of some novel anti-calmodulin drugs. Bioorg Med Chem, 1999, 7, 1559-1565. (Pubitemid 29347122)
36. Schleuning M, Brumme V,WilmannsW: Growth inhibition of human leukemic cell lines by the phenothiazine derivate fluphenazine. Anticancer Res, 1993, 13, 599-602. (Pubitemid 23216952)
37. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology, 1996, 124, 57-73. (Pubitemid 26112775)
38. Seelig A: A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem, 1998, 251, 252-261.
39. Seelig A: How does P-glycoprotein recognize its substrates? J Clin Pharmacol Ther, 1998, 36, 50-54.
40. Seelig A, Blatter LX, Wohnsland F: Substrate recognition by P-glycoprotein and by the multidrug resistance- associated protein MRP1: a comparison. Int J Clin Pharmacol Ther, 2000, 38, 111-121. (Pubitemid 30143145)
41. Seelig A, Gottschlich R, Devant RM: A method to determine the ability of drugs to diffuse through the blood-brain barrier. Proc Natl Acad Sci USA, 1994, 91, 68-72.
42. Seelig A, Landwojtowicz E: Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci, 2000, 12, 31-40.
43. Singh A, Singh S: A cell-based drug efflux assay for analysis of multidrug resistance in cancer patients. Am J Biomed Sci, 2010, 2, 178-183.
44. Snyder SH, Banerjee SP, Yamamura SP, Greenberg D: Drugs, neurotransmitters, and schizophrenia. Science, 1974, 184, 1243-1253.
45. Szwed J, Cieślik-Boczula K, Czarnik-Matusewicz B, Jaszczyszyn A, Ga̧siorowski K, Świa̧tek P, Malinka W: Moving-window 2D correlation spectroscopy in studies of fluphenazine-DPPC dehydrated film as a function of temperature. J Mol Struct, 2010, 974, 192-202.
46. Taheri M, Mahjoubi F, Omranipour R: Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. Genet Mol Res, 2010, 9, 34-40.
47. Tan B, Piwnica-Worms D, Ratner L: Multidrug resistance transporters and modulation. Curr Opin Oncol, 2000, 12, 450-458. (Pubitemid 32268882)
48. Teodori E, Dei S, Scapecchi S, Gualtieri F: The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco, 2002, 57, 385-415. (Pubitemid 34451020)
49. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem, 1992, 267, 24248-24252.
50. Weiss B, Prozialeck WC, Wallace TL: Interaction of drugs with calmodulin. Biochemical, pharmacological and clinical implications. Biochem Pharmacol, 1982, 31, 2217-2226. (Pubitemid 12085283)
51. 4 receptor ligands: relation to antipsychotic action. Eur J Pharmacol, 1998, 351, 273-286.
52. Zamora JM, Pearce HL, Beck WT: Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol, 1988, 33, 454-462.
53. Zorumski CF, Yang J: Non-competitive inhibition of GABA currents by phenothiazines in cultured chick spinal cord and rat hippocampal neurons. Neurosci Lett, 1988, 92, 86-91.